Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

Repligen Corporation is a bioprocessing company focused on the development, production, and commercialization of innovative products used in the process of manufacturing biologic drugs. The Company"s customers include life sciences companies, global biopharmaceutical companies, and contract manufacturers worldwide.
Website: repligen.com



Growth: Good revenue growth rate 10.6%, there is acceleration compared to average historical growth rates 7.3%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -12.8%

Profitability: LTM EBITDA margin is positive, +13.7%. In the last quarter the company beat the estimated EPS, +8.5%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.13 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -6.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 73.0% higher than minimum and 15.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.6x by EV / Sales multiple , the company can be 78.8% overvalued

Insiders: For the last 3 months insiders sold company shares on $6.0 mln (-0.057% of cap.)

Key Financials (Download financials)

Ticker: RGEN
Share price, USD:  (-2.4%)175.8
year average price 158.04  


year start price 148.48 2025-10-29

min close price 101.59 2026-05-14

max close price 194.69 2026-09-29

current price 175.80 2026-10-28
Common stocks: 56 558 000

Dividend Yield:  0.0%
FCF Yield LTM: -6.3%
EV / LTM EBITDA: 88.8x
EV / Sales: 12.1x
Margin (EBITDA LTM / Revenue): 13.7%
Fundamental value created in LTM:
Market Cap ($m): 9 943
Net Debt ($m): -171
EV (Enterprise Value): 9 772
Price to Book: 4.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-14seekingalpha.com

Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-16globenewswire.com

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

2025-12-03seekingalpha.com

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

2025-11-26globenewswire.com

Repligen Corporation to Present at Evercore Healthcare Conference

2025-11-18seekingalpha.com

Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

2025-11-14seekingalpha.com

Repligen: Rare Growth In The Biopharma Supplies Industry

2025-11-11seekingalpha.com

Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript

2025-11-10seekingalpha.com

Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-09-25seekingalpha.com

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

2025-09-04seekingalpha.com

Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272
fillingDate 2025-11-04 2025-08-07 2024-11-18 2024-11-18 2024-05-01 2023-10-31 2023-08-02 2023-05-02 2022-11-01
acceptedDate 2025-11-04 16:07:53 2025-08-07 16:46:31 2025-03-13 19:14:28 2024-11-18 12:10:14 2024-11-18 12:08:36 2024-05-01 16:22:06 2024-11-18 12:06:05 2023-10-31 16:16:16 2023-08-02 16:20:27 2023-05-02 16:42:22 2023-02-22 16:47:17 2022-11-01 16:31:46 2022-02-17 16:32:17 2021-02-24 16:22:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 189M 182M 634M 155M 154M 151M 632M 141M 159M 183M 802M 201M 671M 366M
costOfRevenue 88M 91M 360M 77M 85M 76M 354M 105M 79M 82M 346M 87M 279M 172M
grossProfit 101M 91M 275M 77M 69M 75M 278M 37M 80M 101M 456M 114M 391M 194M
grossProfitRatio 0.532 0.5 0.5 0.446 0.495 0.259 0.502 0.552 0.569
researchAndDevelopmentExpenses 14M 14M 43M 10M 11M 11M 43M 11M 10M 12M 44M 10M 34M 20M
generalAndAdministrativeExpenses 0 0 0 0 0 61M 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 74M 71M 263M 72M 65M 61M 219M 55M 49M 56M 216M 54M 184M 93M
otherExpenses -4M -8M 3M 0 0 -4M -31M 895 000 528 000 77 000 -29M 0 6M 0
operatingExpenses 84M 77M 310M 85M 75M 72M 231M 66M 59M 68M 231M 64M 224M 113M
costAndExpenses 172M 168M 670M 163M 153M 149M 585M 171M 138M 150M 577M 150M 503M 285M
interestIncome 14M 7M 0 0 0 0 0 7M 0 0 7M 0 176 000 2M
interestExpense 27M 6M 23M 0 6M 5M 10M 269 000 274 000 270 000 3M 329 000 13M 12M
depreciationAndAmortization 24M 25M 87M 17M 17M 17M 86M -34M 2M 855 000 57M 8M 38M 27M
ebitda 47M 48M 80M 21M 27M 16M 145M -29M 21M 32M 277M 60M 203M 98M
ebitdaratio 0.249 0.265 0.138 0.178 0.102 -0.206 0.134 0.176 0.301
operatingIncome 17M 14M -35M -8M 1M 2M 48M 5M 19M 31M 225M 53M 167M 81M
operatingIncomeRatio 0.089 0.076 -0.051 0.01 0.013 0.034 0.122 0.171 0.262
totalOtherIncomeExpensesNet 287 000 4M 8M 7M 4M 5M 9M 42M 5M 5M -6M -5M -14M -22M
incomeBeforeTax 17M 18M -27M -1M 5M 2M 57M 12M 25M 36M 219M 47M 154M 59M
incomeBeforeTaxRatio 0.091 0.1 -0.007 0.034 0.014 0.082 0.158 0.198 0.236
incomeTaxExpense 2M 3M -2M -495 000 2M 20 000 21M -7M 5M 7M 33M 7M 25M -709 000
netIncome 15M 15M -26M -654 000 3M 2M 36M 18M 20M 29M 186M 40M 128M 60M
netIncomeRatio 0.079 0.082 -0.004 0.022 0.014 0.129 0.126 0.158 0.201
eps 0.27 0.26 -0.46 0.32 0.059 0.04 0.64 0.33 0.36 0.52 3.35 0.73 2.33 1.14
epsdiluted 0.26 0.26 0.32 0.059 0.04 0.32 0.35 0.51 0.71
weightedAverageShsOut 56M 56M 56M 56M 56M 56M 56M 56M 56M 56M 55M 55M 55M 53M
weightedAverageShsOutDil 57M 57M 56M 57M 56M 57M 56M 57M 57M 57M 57M 57M 57M 54M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-14 2024-11-18 2023-02-22 2022-02-17 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -23M -10M 4M -13M -10M
ebit -6M 59M 220M 165M 71M
nonOperatingIncomeExcludingInterest -29M -12M 4M 2M 10M
netIncomeFromContinuingOperations -26M 36M 186M 128M 60M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -26M 36M 186M 128M 60M
epsDiluted -0.46 0.63 3.24 2.24 1.11

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272
fillingDate 2025-11-04 2025-08-07 2024-11-18 2024-11-18 2024-05-01 2023-10-31 2023-08-02 2023-05-02 2022-11-01
acceptedDate 2025-11-04 16:07:53 2025-08-07 16:46:31 2025-03-13 19:14:28 2024-11-18 12:10:14 2024-11-18 12:08:36 2024-05-01 16:22:06 2024-11-18 12:06:05 2023-10-31 16:16:16 2023-08-02 16:20:27 2023-05-02 16:42:22 2023-02-22 16:47:17 2022-11-01 16:31:46 2022-02-17 16:32:17 2021-02-24 16:22:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 749M 709M 757M 784M 809M 781M 751M 631M 604M 517M 523M 573M 604M 717M
shortTermInvestments 0 0 0 0 0 1 503M 0 0 0 101M 100M 0 0 0
cashAndShortTermInvestments 749M 709M 757M 784M 809M 781M 751M 631M 604M 618M 624M 573M 604M 717M
netReceivables 149M 157M 134M 129M 123M 116M 124M 106M 120M 133M 116M 118M 117M 71M
inventory 160M 156M 143M 182M 191M 198M 202M 211M 241M 245M 238M 243M 184M 95M
otherCurrentAssets 38M 35M 21M 36M 36M 38M 20M 30M 34M 23M 17M 20M 19M 14M
totalCurrentAssets 1 096M 1 057M 1 066M 1 132M 1 159M 1 133M 1 111M 978M 999M 1 019M 998M 953M 932M 902M
propertyPlantEquipmentNet 313M 321M 333M 330M 336M 340M 323M 320M 325M 315M 316M 296M 227M 92M
goodwill 1 113M 1 114M 1 031M 988M 986M 986M 987M 869M 871M 856M 856M 851M 860M 618M
intangibleAssets 395M 406M 398M 381M 380M 388M 407M 344M 352M 347M 361M 360M 337M 287M
goodwillAndIntangibleAssets 1 508M 1 520M 1 429M 1 368M 1 365M 1 374M 1 394M 1 213M 1 222M 1 203M 1 216M 1 211M 1 198M 905M
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 856 000 800 000 749 000 101 000 678 000 866 000 2M 2M 2M 845 000 840 000 2M 2M 2M
otherNonCurrentAssets 5M 3M 868 000 748 000 853 000 956 000 1M 1M 2M 1M 815 000 800 000 615 000 573 000
totalNonCurrentAssets 1 827M 1 845M 1 764M 1 699M 1 703M 1 716M 1 720M 1 536M 1 550M 1 519M 1 533M 1 509M 1 427M 1 001M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 2 924M 2 902M 2 830M 2 831M 2 862M 2 849M 2 831M 2 514M 2 549M 2 538M 2 532M 2 463M 2 358M 1 903M
accountPayables 29M 26M 32M 21M 21M 19M 20M 19M 24M 26M 28M 25M 36M 17M
shortTermDebt 19M 16M 0 12M 82M 79M 69M 3M 3M 8M 285M 297M 255M 244M
taxPayables 0 1M 0 148 000 573 000 2M 7M 2M 5M 3M 2M 4M 5M 1M
deferredRevenue 16M 21M 13M 0 14M 14M 17M 11M 14M 18M 19M 19M 15M 15M
otherCurrentLiabilities 67M 59M 49M 75M 57M 66M 30M 330M 333M 353M 47M 69M 42M 20M
totalCurrentLiabilities 131M 123M 127M 108M 174M 178M 165M 363M 374M 405M 404M 411M 375M 319M
longTermDebt 670M 670M 526M 660M 661M 658M 510M 417M 420M 413M 0 121M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 -18M -48M -43M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 20M 23M 23M 34M 36M 38M 39M 14M 22M 22M 23M 23M 33M 27M
otherNonCurrentLiabilities 20M 24M 36M 12M 4M 4M 25M 18M 48M 43M 62M -125M 97M 1M
totalNonCurrentLiabilities 709M 717M 730M 706M 701M 700M 701M 431M 442M 435M 217M 217M 233M 55M
otherLiabilities 0 0 0 0 0 0 0 -268M -237M -242M 0 0 0 0
capitalLeaseObligations 151M 152M 161M 151M 156M 154M 132M 134M 137M 136M 138M 134M 111M 32M
totalLiabilities 841M 840M 857M 814M 876M 879M 866M 526M 578M 598M 621M 627M 608M 374M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 563 000 563 000 561 000 560 000 559 000 559 000 558 000 558 000 557 000 556 000 556 000 555 000 553 000 548 000
retainedEarnings 443M 428M 407M 441M 444M 441M 433M 464M 446M 426M 397M 349M 194M 66M
accumulatedOtherComprehensiveIncomeLoss -4M -2M -53M -35M -44M -43M -38M -44M -37M -31M -34M -55M -17M 2M
othertotalStockholdersEquity 1 644M 1 635M 1 610M 1 586M 1 572M 43M 37M 31M 1 541M
totalStockholdersEquity 2 083M 2 062M 1 973M 2 017M 1 986M 1 971M 1 965M 464M 446M 426M 1 911M 1 835M 1 750M 1 529M
totalEquity 2 083M 2 062M 1 973M 2 017M 1 986M 1 971M 1 965M 464M 446M 426M 1 911M 1 835M 1 750M 1 529M
totalLiabilitiesAndStockholdersEquity 2 924M 2 902M 2 831M 2 862M 2 849M 990M 2 549M 2 538M 2 463M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 924M 2 902M 2 830M 2 831M 2 862M 2 849M 2 831M 990M 2 549M 2 538M 2 532M 2 463M 2 358M 1 903M
totalInvestments 0 0 0 0 809M 1 503M 0 0 0 101M 100M 0 0 0
totalDebt 689M 686M 686M 672M 743M 738M 712M 420M 423M 421M 423M 419M 366M 275M
netDebt -60M -23M -71M -111M -66M -43M -40M -211M -181M -96M -100M -155M -238M -442M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-14 2024-11-18 2023-02-22 2022-02-17 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 134M 124M 116M 117M 71M
otherReceivables 0 0 0 0 0
prepaids 11M 14M 2M 7M 5M
totalPayables 34M 26M 30M 41M 18M
otherPayables 1M 7M 2M 5M 1M
accruedExpenses 16M 17M 16M 14M 16M
capitalLeaseObligationsCurrent 15M 6M 7M 8M 5M
capitalLeaseObligationsNonCurrent 146M 127M 131M 102M 26M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 617M 1 569M 1 547M 1 572M 1 461M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN RGEN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272 730 272
fillingDate 2025-11-04 2025-08-07 2024-11-18 2024-11-18 2024-05-01 2023-10-31 2023-08-02 2023-05-02 2022-11-01
acceptedDate 2025-11-04 16:07:53 2025-08-07 16:46:31 2025-03-13 19:14:28 2024-11-18 12:10:14 2024-11-18 12:08:36 2024-05-01 16:22:06 2024-11-18 12:06:05 2023-10-31 16:16:16 2023-08-02 16:20:27 2023-05-02 16:42:22 2023-02-22 16:47:17 2022-11-01 16:31:46 2022-02-17 16:32:17 2021-02-24 16:22:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 15M 15M -26M -653 000 3M 2M 42M 18M 20M 29M 186M 40M 128M 60M
depreciationAndAmortization 34M 25M 87M 17M 17M 17M 68M 20M 16M 15M 57M 13M 38M 27M
deferredIncomeTax -3M -1M 0 3M -2M -833 000 2M -8M -1M -1M -1M 984 000 7M -4M
stockBasedCompensation 0 8M 48M 23M 9M 9M 26M 6M 5M 7M 27M 6M 28M 17M
changeInWorkingCapital 12M -12M 61M 6M 11M 14M -9M 36M -8M -40M -70M -17M -102M -49M
accountsReceivables 8M -5M -14M 0 0 7M -3M 13M 12M -17M -4M -176 000 -47M -21M
inventory -5M 3M 57M 0 7M 3M 41M 28M 3M -6M -57M -6M -90M -30M
accountsPayables 3M -2M 13M -2M 2M -645 000 -10M -5M -3M -1M -8M -16M 20M 2M
otherWorkingCapital 5M -8M 5M 8M 1M 5M -36M -573 000 -21M 24M -841 000 6M 15M -930 000
otherNonCashItems -10M -6M 5M 4M 4M 4M -15M -34M 2M 835 000 -27M -2M 20M 12M
netCashProvidedByOperatingActivities 48M 29M 175M 49M 42M 45M 114M 39M 34M 11M 172M 41M 119M 63M
investmentsInPropertyPlantAndEquipment -5M -7M -26M 0 -5M -8M -36M -9M -9M -9M -85M -58M -71M -22M
acquisitionsNet 0 -234 000 -55M 0 0 0 -187M 256 000 0 0 0 0 -150M -175M
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 -100M 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 102M 0 0 0 0 0 0 0
otherInvestingActivites -2M -504 000 -6M -3M 11 000 21 000 74M 0 13 000
netCashUsedForInvestingActivites -8M -8M -6M -7M -8M -9M 65M -9M -57M
debtRepayment 0 0 0 0 0 -24 000 -9000 0 0
commonStockIssued 678 000 0 -541 000 0 541 000 -10000 -3000 29 000 0
commonStockRepurchased 0 -676 000 0 9M -1M -8M -14M -10000 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -917 000 -9M -70M -5M -10M -430 000 -9M -10M 1M
netCashUsedProvidedByFinancingActivities -239 000 -10M -70M -6M -9M -778 000 -9M -10M 1M
effectOfForexChangesOnCash -185 000 987 000 -77 000 961 000 -488 000 2M -12M -3M -3M 993 000 -6M -8M -12M 13M
netChangeInCash 40M 12M 6M -25M 29M 29M 228M 27M 87M -7M -80M -23M -113M 180M
cashAtEndOfPeriod 749M 709M 757M 0 809M 781M 751M 631M 604M 517M 523M 573M 604M 717M
cashAtBeginningOfPeriod 709M 697M 751M 809M 781M 751M 523M 604M 517M 523M 604M 597M 717M 537M
operatingCashFlow 48M 29M 175M 49M 42M 45M 114M 39M 34M 11M 172M 41M 119M 63M
capitalExpenditure -5M -8M -33M -7M -7M -8M -39M -9M -9M -9M -133M -58M -71M -26M
freeCashFlow 43M 21M 142M 42M 35M 36M 75M 30M 25M 2M 39M -16M 48M 36M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-14 2024-11-18 2023-02-22 2022-02-17 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -6M -3M -48M 0 -4M
netCashProvidedByInvestingActivities -86M -123M -233M -221M -201M
netDebtIssuance -70M 290M 0 -21 000 0
longTermNetDebtIssuance -70M 290M 0 -21 000 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 4M -14M 0 4M 298M
netCommonStockIssuance 4M -14M 0 4M 298M
commonStockIssuance 4M 0 0 4M 298M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -17M -27M -13M -3M 8M
netCashProvidedByFinancingActivities -83M 249M -13M 961 000 306M
incomeTaxesPaid 19M 27M 34M 0 10M
interestPaid 6M 988 000 1M 0 1M

Earning call transcript

2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-07-29 ET (fiscal 2025 q2)
2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-20 ET (fiscal 2024 q4)
2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-07-30 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-21 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-08-26 ET
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
2026-07-28 ET
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
2026-07-15 ET
Repligen to Report Second Quarter 2026 Financial Results
2026-05-22 11:30 ET
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
2026-05-20 11:30 ET
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
2026-05-07 11:30 ET
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
2026-05-05 ET
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
2026-04-22 ET
Repligen to Report First Quarter 2026 Financial Results
2026-04-17 ET
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
2026-03-05 ET
Repligen Corporation to Present at Upcoming March Conferences
2026-02-24 ET
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
2026-02-10 12:30 ET
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
2026-01-06 ET
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
2025-12-18 ET
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
2025-12-16 ET
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
2025-11-26 ET
Repligen Corporation to Present at Evercore Healthcare Conference
2025-11-04 ET
Repligen Corporation to Present at Upcoming November Conferences
2025-10-28 11:30 ET
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
2025-10-15 ET
Repligen to Report Third Quarter 2025 Financial Results
2025-08-22 ET
Repligen Corporation to Present at Upcoming September Conferences
2025-07-31 ET
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
2025-07-29 ET
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
2025-07-17 ET
Repligen to Report Second Quarter 2025 Financial Results
2025-05-27 ET
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
2025-05-22 ET
Repligen Corporation to Present at William Blair Growth Conference
2025-05-07 ET
Repligen Corporation to Present at Upcoming May Investor Conferences
2025-04-29 ET
Repligen Reports First Quarter 2025 Financial Results
2025-04-15 ET
Repligen to Report First Quarter 2025 Financial Results
2025-04-08 ET
Repligen Appoints Jacob Johnson As Vice President Investor Relations
2025-02-20 ET
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-11 ET
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
2025-01-07 ET
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
2025-01-06 ET
Repligen Launches the CTech™ SoloVPE® PLUS System
2024-12-12 ET
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
2024-12-09 ET
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
2024-11-12 12:30 ET
Repligen Reports Third Quarter 2024 Financial Results
2024-11-05 12:30 ET
Repligen Corporation to Present at Upcoming Investor Conferences
2024-10-31 11:30 ET
Repligen to Report Third Quarter 2024 Financial Results
2024-09-24 11:30 ET
Repligen Opens Training & Innovation Center to Elevate Customer Experience
2024-08-23 11:30 ET
Repligen Corporation to Present at Wells Fargo Healthcare Conference
2024-07-30 11:30 ET
Repligen Reports Second Quarter 2024 Financial Results
2024-07-29 20:00 ET
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
2024-07-16 11:30 ET
Repligen to Report Second Quarter 2024 Financial Results
2024-06-13 11:00 ET
Repligen Announces CEO Transition Plan
2024-05-22 11:30 ET
Repligen Corporation to Present at Upcoming June Investor Conferences
2024-05-07 11:30 ET
Repligen Corporation to Present at Upcoming May Investor Conferences
2024-05-01 11:30 ET
Repligen Reports First Quarter 2024 Financial Results
2024-04-17 11:30 ET
Repligen to Report First Quarter 2024 Financial Results
2024-03-19 11:30 ET
Repligen Appoints Maggie A. Pax to Board of Directors
2024-02-21 12:30 ET
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-07 12:30 ET
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
2023-12-19 12:30 ET
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-07 12:30 ET
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
2023-12-07 ET
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
2023-11-14 12:30 ET
Repligen Announces Publication of the Company’s 2022 Sustainability Report
2023-11-07 12:30 ET
Repligen Corporation to Present at Upcoming Investor Conferences
2023-11-02 11:30 ET
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
2023-10-31 11:30 ET
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
2023-10-17 11:30 ET
Repligen to Report Third Quarter 2023 Financial Results
2023-10-02 11:30 ET
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
2023-09-26 11:30 ET
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
2023-09-12 11:30 ET
Repligen Appoints Jason K. Garland as Chief Financial Officer
2023-09-01 11:30 ET
Repligen Corporation to Present at Wells Fargo Healthcare Conference
2023-08-17 12:00 ET
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
2023-08-02 11:30 ET
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
2023-07-19 11:30 ET
Repligen to Report Second Quarter 2023 Financial Results
2023-05-31 11:30 ET
Repligen Corporation to Present at Upcoming Investor Conferences
2023-05-02 11:30 ET
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
2023-04-18 11:30 ET
Repligen to Report First Quarter 2023 Financial Results
2023-03-14 11:30 ET
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
2023-02-22 12:30 ET
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-09 12:30 ET
Repligen Appoints Martin D. Madaus to Board of Directors
2023-02-08 12:30 ET
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
2023-01-03 12:30 ET
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-11-08 12:30 ET
Repligen Corporation to Present at Upcoming Investor Conferences
2022-11-01 11:30 ET
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
2022-11-01 11:00 ET
Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
2022-10-12 11:30 ET
Repligen to Report Third Quarter 2022 Financial Results
2022-09-19 20:01 ET
Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
2022-08-24 11:30 ET
Repligen To Host Investor Day 2022
2022-08-02 11:30 ET
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
2022-07-19 11:30 ET
Repligen to Report Second Quarter 2022 Financial Results
2022-05-26 20:30 ET
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
2022-05-25 11:30 ET
Repligen Corporation to Present at Upcoming Investor Conferences
2022-04-27 11:30 ET
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
2022-04-13 11:30 ET
Repligen to Report First Quarter 2022 Financial Results
2022-03-18 11:30 ET
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
2022-02-17 12:30 ET
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-15 12:30 ET
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
2022-02-11 12:30 ET
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
2022-02-03 14:30 ET
Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
2021-12-30 12:30 ET
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-11-12 12:30 ET
Repligen Corporation to Present at Upcoming Investor Conferences
2021-11-05 11:30 ET
Repligen Releases Inaugural Sustainability Report
2021-10-28 11:30 ET
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
2021-10-14 11:30 ET
Repligen to Report Third Quarter 2021 Financial Results
2021-09-16 11:40 ET
Repligen Announces Agreement to Acquire Avitide Inc.
2021-09-09 11:30 ET
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
2021-09-09 11:30 ET
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
2021-07-27 11:30 ET
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
2021-07-13 11:30 ET
Repligen to Report Second Quarter 2021 Financial Results
2021-06-22 10:30 ET
Repligen Corporation Announces Agreement to Acquire Polymem S.A.
2021-05-25 11:30 ET
Repligen Corporation to Present at Upcoming Investor Conferences
2021-05-04 11:30 ET
Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
2021-04-20 11:30 ET
Repligen to Report First Quarter 2021 Financial Results
2021-03-17 11:30 ET
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
2021-03-03 12:30 ET
Repligen Corporation to Present at Barclays Global Healthcare Conference
2021-02-24 12:30 ET
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-22 12:30 ET
Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
2021-02-11 20:00 ET
Repligen to Report Fourth Quarter and Full Year 2020 Financial Results
2021-02-08 12:36 ET
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
2021-02-08 12:36 ET
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
2021-01-04 18:00 ET
Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-10 21:18 ET
Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Option
2020-12-08 17:20 ET
EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen
2020-12-08 02:40 ET
Repligen Corporation Prices Public Offering of Shares of Common Stock
2020-12-07 12:21 ET
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
2020-11-05 12:30 ET
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
2020-10-27 20:15 ET
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
2020-10-22 11:30 ET
Repligen to Report Third Quarter 2020 Financial Results
2020-10-01 10:30 ET
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
2020-07-30 11:30 ET
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
2020-07-15 11:30 ET
Repligen to Report Second Quarter 2020 Financial Results
2020-06-29 11:30 ET
Repligen Announces Agreement to Acquire Engineered Molding Technology
2020-06-15 11:30 ET
Repligen Appoints Carrie Eglinton Manner to Board of Directors
2020-05-06 11:30 ET
Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
2020-04-22 11:30 ET
Repligen to Report First Quarter 2020 Financial Results
2020-02-27 12:30 ET
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
2020-02-20 12:30 ET
Repligen Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-06 12:30 ET
Repligen to Report Fourth Quarter and Full Year 2019 Financial Results
2020-01-07 12:30 ET
Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-10-31 11:30 ET
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
2019-10-23 14:29 ET
Repligen to Report Third Quarter 2019 Financial Results

SEC forms

Show financial reports only

SEC form 8
2026-10-27 00:00 ET
Repligen published news for 2026 q3
SEC form 8
2026-10-27 00:00 ET
Repligen reported for 2026 q3
SEC form 10
2026-07-29 20:19 ET
Repligen reported for 2026 q2
SEC form 8
2026-07-28 11:13 ET
Repligen published news for 2026 q2
SEC form 8
2026-07-28 11:13 ET
Repligen published news for 2026 q2
SEC form 10
2026-05-06 20:08 ET
Repligen reported for 2026 q1
SEC form 8
2026-05-05 11:06 ET
Repligen published news for 2026 q1
SEC form 8
2026-05-05 11:06 ET
Repligen published news for 2026 q1
SEC form 10
2026-02-26 21:03 ET
Repligen published news for 2025 q4
SEC form 8
2026-02-24 07:33 ET
Repligen published news for 2025 q4
SEC form 8
2026-02-24 07:33 ET
Repligen reported for 2025 q4
SEC form 8
2025-10-28 11:33 ET
Repligen published news for 2025 q3
SEC form 8
2025-10-28 11:33 ET
Repligen reported for 2025 q3
SEC form 10
2025-08-07 20:46 ET
Repligen reported for 2025 q2
SEC form 8
2025-07-29 11:31 ET
Repligen published news for 2025 q2
SEC form 8
2025-07-29 11:31 ET
Repligen reported for 2025 q2
SEC form 10
2025-04-29 20:17 ET
Repligen published news for 2025 q1
SEC form 10
2025-04-29 00:00 ET
Repligen reported for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Repligen published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Repligen published news for 2025 q1
SEC form 10
2025-03-14 00:00 ET
Repligen published news for 2024 q4
SEC form 10
2025-03-13 23:14 ET
Repligen published news for 2024 q4
SEC form 8
2025-02-20 07:45 ET
Repligen published news for 2024 q4
SEC form 8
2025-02-20 07:45 ET
Repligen reported for 2024 q4
SEC form 10
2024-11-18 12:10 ET
Repligen published news for 2024 q3
SEC form 10
2024-11-18 00:00 ET
Repligen published news for 2024 q3
SEC form 8
2024-11-12 07:44 ET
Repligen published news for 2024 q3
SEC form 8
2024-11-12 07:44 ET
Repligen published news for 2024 q3
SEC form 8
2024-11-12 07:44 ET
Repligen published news for 2024 q3
SEC form 8
2024-09-18 00:00 ET
Repligen published news for 2024 q2
SEC form 8
2024-09-18 00:00 ET
Repligen published news for 2024 q2
SEC form 10
2024-07-30 17:04 ET
Repligen published news for 2024 q2
SEC form 8
2024-07-30 07:46 ET
Repligen published news for 2024 q2
SEC form 8
2024-07-30 07:46 ET
Repligen reported for 2024 q2
SEC form 10
2024-07-30 00:00 ET
Repligen published news for 2024 q2
SEC form 10
2024-05-01 16:22 ET
Repligen published news for 2024 q1
SEC form 8
2024-05-01 07:44 ET
Repligen published news for 2024 q1
SEC form 8
2024-05-01 07:44 ET
Repligen reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
Repligen published news for 2024 q1
SEC form 10
2024-02-22 16:26 ET
Repligen published news for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Repligen published news for 2023 q4
SEC form 8
2024-02-21 07:47 ET
Repligen published news for 2023 q4
SEC form 8
2024-02-21 07:47 ET
Repligen reported for 2023 q4
SEC form 10
2023-10-31 16:16 ET
Repligen published news for 2023 q3
SEC form 8
2023-10-31 07:48 ET
Repligen reported for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Repligen published news for 2023 q3
SEC form 10
2023-08-02 16:20 ET
Repligen published news for 2023 q2
SEC form 6
2023-08-02 07:54 ET
Repligen reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Repligen published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Repligen published news for 2023 q2
SEC form 10
2023-05-02 00:00 ET
Repligen published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Repligen published news for 2023 q1
SEC form 6
2023-04-12 07:31 ET
Repligen published news for 2023 q1
SEC form 10
2023-02-22 16:47 ET
Repligen reported for 2022 q4
SEC form 6
2023-02-22 07:55 ET
Repligen published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Repligen reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Repligen reported for 2022 q4
SEC form 6
2023-02-09 07:42 ET
Repligen published news for 2022 q4
SEC form 6
2023-02-08 18:09 ET
Repligen published news for 2022 q4
SEC form 10
2022-11-01 16:31 ET
Repligen reported for 2022 q3
SEC form 6
2022-11-01 07:54 ET
Repligen published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Repligen reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Repligen reported for 2022 q3
SEC form 10
2022-08-02 16:31 ET
Repligen reported for 2022 q2
SEC form 6
2022-08-02 08:11 ET
Repligen published news for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Repligen reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Repligen reported for 2022 q2
SEC form 6
2022-06-01 17:25 ET
Repligen published news for 2022 q1
SEC form 6
2022-05-31 18:34 ET
Repligen published news for 2022 q1
SEC form 10
2022-04-27 16:15 ET
Repligen reported for 2022 q1
SEC form 6
2022-04-27 07:47 ET
Repligen published news for 2022 q1
SEC form 10
2022-04-27 00:00 ET
Repligen reported for 2022 q1
SEC form 8
2022-04-27 00:00 ET
Repligen reported for 2022 q1
SEC form 6
2022-04-11 17:14 ET
Repligen published news for 2022 q1
SEC form 6
2022-03-08 07:43 ET
Repligen published news for 2021 q4
SEC form 10
2022-02-17 16:32 ET
Repligen published news for 2021 q4
SEC form 6
2022-02-17 07:49 ET
Repligen published news for 2021 q4
SEC form 10
2022-02-17 00:00 ET
Repligen published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Repligen published news for 2021 q4
SEC form 6
2022-01-04 07:00 ET
Repligen published news for 2021 q4
SEC form 6
2021-12-16 07:11 ET
Repligen published news for 2021 q3
SEC form 10
2021-10-28 16:51 ET
Repligen published news for 2021 q3
SEC form 6
2021-10-28 07:55 ET
Repligen published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Repligen published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Repligen published news for 2021 q3
SEC form 6
2021-09-16 07:53 ET
Repligen published news for 2021 q2
SEC form 6
2021-09-03 07:45 ET
Repligen published news for 2021 q2
SEC form 10
2021-07-27 16:47 ET
Repligen published news for 2021 q2
SEC form 6
2021-07-27 07:42 ET
Repligen published news for 2021 q2
SEC form 10
2021-07-27 00:00 ET
Repligen published news for 2021 q2
SEC form 8
2021-07-27 00:00 ET
Repligen published news for 2021 q2
SEC form 6
2021-05-20 21:00 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-19 07:00 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-18 07:52 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-18 07:50 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-18 07:49 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-17 21:59 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-17 21:57 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-17 21:56 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-17 21:52 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-17 21:50 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-13 17:01 ET
Repligen published news for 2021 q1
SEC form 10
2021-05-04 16:21 ET
Repligen published news for 2021 q1
SEC form 6
2021-05-04 07:54 ET
Repligen published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Repligen published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Repligen published news for 2021 q1
SEC form 6
2021-04-21 07:22 ET
Repligen published news for 2021 q1
SEC form 6
2021-04-08 19:55 ET
Repligen published news for 2021 q1
SEC form 6
2021-03-08 19:54 ET
Repligen published news for 2020 q4
SEC form 6
2021-03-08 19:43 ET
Repligen published news for 2020 q4
SEC form 10
2021-02-24 16:22 ET
Repligen published news for 2020 q4
SEC form 6
2021-02-24 07:54 ET
Repligen published news for 2020 q4
SEC form 6
2021-01-28 16:01 ET
Repligen published news for 2020 q4
SEC form 6
2020-12-08 16:05 ET
Repligen published news for 2020 q3
SEC form 10
2020-11-05 16:51 ET
Repligen published news for 2020 q3
SEC form 6
2020-11-05 07:51 ET
Repligen published news for 2020 q3
SEC form 6
2020-10-27 16:17 ET
Repligen published news for 2020 q3